Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > LATEST
LATEST
-
ARCHIVE Exelon Skin Patch Recommended for European Approval: Novartis
August 6, 2007
-
ARCHIVE Metronidazole-Based 3-Drug Combination to Be Approved for Hp Eradication
August 6, 2007
-
ARCHIVE 10 New Drugs (6 APIs) Recommended for Approval
August 6, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF
August 6, 2007
-
COLUMN Maurer's Healthcare Insight (88)
August 6, 2007
-
ARCHIVE TOPICS/Asahi Kasei Publishes FY2007 IP Report
August 6, 2007
-
ARCHIVE SURVEY/Majority of Users Do not Obtain Viagra from Hospitals
August 6, 2007
-
ARCHIVE Kyowa Hakko Licenses New Antibody Engineering Technology to BioWa
August 6, 2007
-
ARCHIVE Merck to Acquire NovaCardia
August 6, 2007
-
ARCHIVE R&D NEWS IN BRIEF
August 6, 2007
-
ARCHIVE Eisai Licenses Eszopiclone from Sepracor
August 6, 2007
-
ARCHIVE Elmed Eisai Conducts PMS on 2 of Its Generic Products
August 6, 2007
-
ARCHIVE Revised Therapeutic GL on Breast Cancer Published
July 30, 2007
-
ARCHIVE NEW PRODUCTS
July 30, 2007
-
ARCHIVE Eisai to Launch 3 Major Drugs by FY2011: Mr Naito
July 30, 2007
-
ARCHIVE Prices Should Not Be Cut during Patent Life If Yakkasa Is Smaller than “Dispensing Margins”: EFPIA
July 30, 2007
-
ARCHIVE Long-Listed Drugs Should Be Priced Higher Than Generics: Mr Ohyagi
July 30, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF
July 30, 2007
-
ARCHIVE Kyowa Hakko Committed to Successively Developing New Drugs: President Dr Matsuda
July 30, 2007
-
ARCHIVE 3rd Seminar on MR Mammography Fields Hottest Topics on Breast Cancer MRI
July 30, 2007
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…